Where does Medtronic Vascular Galway Unlimited Company rank among US patent assignees?

According to USPTO PatentsView (2015–2025 granted utility patents), Medtronic Vascular Galway Unlimited Company ranks #5,381 of 49,997 assignees by granted-patent volume, the same sort as the companies listing and top-holders ranking. See /methodology/#corpus-placement.

How many patents does Medtronic Vascular Galway Unlimited Company hold?

Medtronic Vascular Galway Unlimited Company holds 64 US utility patents granted between 2015 and 2025, spanning 10 technology areas.

What is Medtronic Vascular Galway Unlimited Company's Innovation Score?

Medtronic Vascular Galway Unlimited Company has an Innovation Score of 41.9 out of 100 (top 32% of the corpus). This composite metric weighs portfolio volume (40%), grant velocity (20%), technology breadth (25%), and claim depth (15%).

Is Medtronic Vascular Galway Unlimited Company's patent grant rate increasing or decreasing?

Medtronic Vascular Galway Unlimited Company's recent grant velocity is -32% compared to the prior five-year period (grant years, not application filing dates). Grant activity has slowed relative to earlier years.

What does claim depth mean for Medtronic Vascular Galway Unlimited Company's patents?

Medtronic Vascular Galway Unlimited Company's patents average 16.6 claims each. This is an aggregate descriptive count from the grant record; it does not establish claim scope, legal strength, enforceability, or design-around risk.

USPTO 2015–2025 USPTO PatentsView Foreign Corporation

Medtronic Vascular Galway Unlimited Company

Q: What technology areas does Medtronic Vascular Galway Unlimited Company focus on?

Medtronic Vascular Galway Unlimited Company's top technology area is A61F (Filters Implantable Into Blood VESSELS; PROSTHESES; Devices Providing Patency TO, OR Preventing Collapsing OF, Tubular Structures OF THE Body, e.g. STENTS; Orthopaedic, Nursing OR Contraceptive DEVICES; FOMENTATION; Treatment OR Protection OF Eyes OR EARS; Bandages, Dressings OR Absorbent PADS; Firs) with 58 patents, ranking #98 of 3,082 assignees active in that subclass. Grants appear in 10 CPC subclasses total.

Q: How is the Medtronic Vascular Galway Unlimited Company patent data sourced?

All patent data comes from USPTO PatentsView, a public research dataset maintained by the United States Patent and Trademark Office covering US granted utility patents from 2015 to 2025.

USPTO PatentsView assignee record - 64 granted patents across 10 technology areas, recorded in grant years 2015–2025. Grant-trend analysis is cross-referenced to USPTO Patent Public Search; it does not measure application filings, current R&D, or legal strength. Primary class: A61F (Filters Implantable Into Blood VESSELS; PROSTHESES; Devices Providing Patency TO, OR Preventing Collapsing OF, Tubular Structures OF THE Body, e.g. STENTS; Orthopaedic, Nursing OR Contraceptive Device).

Compiled by PlainPatent · May 15, 2026

RSS updates for this company

Explore the portfolio See the ranking

The verdict

According to USPTO PatentsView, Medtronic ranks #5,381 of 49,997 tracked US assignees by granted-patent volume, with 64 patents across 10 technology areas.

#5,381
of 49,997 US assignees by volume: Top 32%
by Innovation Score (41.9/100): 16.6
avg claims per patent: -32%
grant velocity, last 5 yrs

USPTO PatentsView assignee plate

Corpus R5381 · Foreign Corporation #5,381 · 64 grants

GRANTS-SMALL · UPPER-Q · PHOTO-FINISH · CPC-FOCUS · INNOV-PAR · CLAIMS-RICH · TYPE-FRNCORP · VEL-DOWN · BOOK-FULL

GRANTS-SMALL 64 grants
UPPER-Q #5,381/49,997
PHOTO-FINISH Light Field Lab
CPC-FOCUS A61F · 10 areas
INNOV-PAR 41.9/100
CLAIMS-RICH 16.6 claims/avg
TYPE-FRNCORP Foreign Corp
VEL-DOWN -32% vel
BOOK-FULL 10/10 fields

Nearest grant-volume peer: Light Field Lab, Inc. (±0 grants)

Instrument codes from this assignee’s USPTO PatentsView grant sheet: volume band, corpus rank, photo-finish peer, lead CPC, Innovation Score, claim depth, assignee type, velocity, and book completeness. Not a USPTO rating of patent strength.

How Medtronic’s 41.9 Innovation Score adds up

The same four weighted components behind every Innovation Score on PlainPatent: portfolio volume, grant velocity, technology breadth, and claim depth.

Volume 14.4 pts (34%) Velocity 6.3 pts (15%) Breadth 11.2 pts (27%) Claim depth 10.0 pts (24%)

Qualcomm Incorporated · highest

85
Bestechnic (Shanghai) · near

42
Ibex PT Holdings · near

42
Medtronic Vascular… · this assignee

42
MGC Filsheet · near

42
Xieon Networks r l · near

42
3D Lighting… · lowest

7

What this shows Medtronic's Innovation Score is 41.9/100 (top 32% of the PatentsView-derived corpus). The chart places that score against the nearest Innovation Score peers plus corpus poles, not a reprint of the volume ranking.

Does more volume mean deeper claims for Medtronic?

Each dot is one of Medtronic’s 8 nearest volume peers (same corpus rank neighbourhood as the chart above), placed by total granted patents (horizontal) against average claims per patent (vertical). Medtronic’s own 16.6 claims/patent is at or below the 17.9 median for these volume peers. Volume here does not track with deeper claims; several lower-volume peers claim more thoroughly per patent.

Medtronic vs its 8 nearest volume peers: granted patents vs average claims per patent. Source: USPTO PatentsView.

Where Medtronic's grants concentrate

Medtronic Vascular Galway Unlimited Company is a focused PatentsView assignee: 10 CPC subclasses with 90.6% of grants classified under A61F (Filters Implantable Into Blood VESSELS; PROSTHESES; Devices Providing Patency TO, OR Preventing Collapsing OF, Tubular Structures OF THE Body, e.g. STENTS; Orthopaedic, Nursing OR Contraceptive Device). Peak complete grant year is 2016 (11 grants) versus a trough of 3 in 2021. By volume, Medtronic sits between Light Field Lab, Inc. and Mid-West Metal Products Company, Inc..

Medtronic's three-year grant acceleration

Medtronic Vascular Galway Unlimited Company shows 16 grants in 2022–2024 against only 17 in 2019–2021. That prior window is too thin for a growth multiple (rename and spin-out assignees look artificially high when the baseline is near zero), so PlainPatent withholds a ranked acceleration claim here.

Light Field Lab

64
Liqui-box

64
Mc10

64
Mechoshade Systems

64
Mitek Systems

64
Medshine Discovery

64
Meritor Heavy Veh…

64
Mid-west Metal Pr…

64
Medtronic Vascula… ◀

64

What this shows Medtronic holds 64 patents at rank #5,379, shown against the 8 assignees closest to it in grant volume rather than the industry's largest filers.

Companies ranked near Medtronic

By rank, the assignees closest to #5,379 in granted patent volume.

Leaders in A61F (Filters Implantable Into Blood Vessels)

Other assignees with the most granted patents in Medtronic's primary technology class.

Assignees with similar portfolio profiles

Two PlainPatent-derived peer sets for Medtronic, neither rank-band nor same-CPC leaders (those blocks stay above). In A61F (Filters Implantable Into Blood Vessels), Medtronic ranks #98 of 3,082 assignees by patent count in that subclass.

Similar innovation score

Nearest assignees by Innovation Score (42 here).

Xieon Networks S.a.r.l. 42 MGC Filsheet Co., Ltd. 42 Bestechnic (Shanghai) Co., Ltd. 42 Ibex PT Holdings Co., Ltd. 42

Similar claim depth

Nearest assignees by average claims per patent (16.6 here).

Amesbury Group, Inc. 16.6 avg University of New Hempshire 16.6 avg Harsco Technologies LLC 16.6 avg Fluor Technologies Corporation 16.6 avg

Medtronic's Innovation Score vs. every tracked assignee

Composite of portfolio volume, grant velocity, technology breadth, and claim depth (0–100)

42 Top 32% higher than 68% of 49,997 US assignees

Each bar is a band; taller bars hold more US assignees. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count, share, and where it sits relative to this entry.

Source USPTO PatentsView, PlainPatent Innovation Score · 2015–2025

USPTO utility patent grants by year · 2015–2025

Grants by year

Teal-shaded recent years (2020–present) versus the 2015–2019 baseline. Full figures in the table below.

View data table

Medtronic Vascular Galway Unlimited Company patent grants by year, 2015–2025
Year	Patents Granted	Share of Period
2015	5	7.8%
2016	11	17.2%
2017	5	7.8%
2018	8	12.5%
2019	8	12.5%
2020	6	9.4%
2021	3	4.7%
2022	7	10.9%
2023	5	7.8%
2024	4	6.3%
2025partial year	2	3.1%

Which technologies does Medtronic Vascular Galway Unlimited Company patent most?

A61F - Filters Implantable Into Blood VESSELS; PROSTHESES; Devices Providing Patency TO, OR Preventing Collapsing OF, Tubular Structures OF THE Body, e.g. STENTS; Orthopaedic, Nursing OR Contraceptive DEVICES; FOMENTATION; Treatment OR Protection OF Eyes OR EARS; Bandages, Dressings OR Absorbent PADS; Firs 58

A61B - DIAGNOSIS; SURGERY; Identification 11

Y10T - Technical Subjects Covered BY Former US Classification 8

A61M - Devices FOR Introducing Media Into, OR Onto, THE Body ; Devices FOR Transducing Body Media OR FOR Taking Media From THE Body ; Devices FOR Producing OR Ending Sleep OR Stupor 7

B23P - Metal-working NOT Otherwise Provided FOR; Combined OPERATIONS; Universal Machine Tools 3

A61N - ELECTROTHERAPY; MAGNETOTHERAPY; Radiation THERAPY; Ultrasound Therapy 3

B23B - TURNING; Boring 1

G01M - Testing Static OR Dynamic Balance OF Machines OR STRUCTURES; Testing OF Structures OR Apparatus, NOT Otherwise Provided FOR 1

G01B - Measuring Length, Thickness OR Similar Linear DIMENSIONS; Measuring ANGLES; Measuring AREAS; Measuring Irregularities OF Surfaces OR Contours 1

F04C - Rotary-piston, OR Oscillating-piston, Positive-displacement Machines FOR Liquids ; Rotary-piston, OR Oscillating-piston, Positive-displacement Pumps 1

Top 10 of 10 technology areas

More on this record

Data Source

USPTO PatentsView, US granted patents 2015–2025

View all rankings → How is Innovation Score calculated?

What to do with this data

Medtronic Vascular Galway Unlimited Company's patent record in context - here's where to go next.

Medtronic Vascular Galway Unlimited Company's lead technology class is A61F (Filters Implantable Into Blood VESSELS; PROSTHESES; Devices Providing Patency TO, OR Preventing Collapsing OF, Tubular Structures OF THE Body, e.g. STENTS; Orthopaedic, Nursing OR Contraceptive Device), 90.6% of its portfolio - see every assignee active in that class. Explore A61F
Ranked #5,381 of 49,997 tracked assignees by patent volume - see the full leaderboard. See the ranking
Compare Medtronic Vascular Galway Unlimited Company against Light Field Lab, Inc., an assignee filing at a similar volume. Compare portfolios
Innovation Score of 41.9/100 blends volume, velocity, technology breadth, and claim depth. How it's calculated

Figures reflect USPTO PatentsView grant data through May 2026; pending applications not yet granted are not counted.

Data sourced from USPTO PatentsView - official U.S. government patent data. See our methodology for computation details. Retrieved and formatted by PlainPatent

Disclaimer: This information is provided for informational purposes only and does not constitute professional advice. Data is sourced from the USPTO PatentsView database. Consult a qualified professional before making decisions based on this data.

Read our methodology - how this data is sourced, computed, and verified.

Data sources used on this page

USPTO PatentsView - the disambiguated bulk patent-grant, assignee, and CPC data this page's figures are derived from. patentsview.org
Cooperative Patent Classification (CPC) - the joint USPTO/EPO classification scheme used to group patents by technology area. cooperativepatentclassification.org
USPTO Patent Public Search - the official interface to verify the status of any individual patent. ppubs.uspto.gov

Compiled by PlainPatent, US Patent Intelligence Editorial Process · May 15, 2026

Every figure on PlainPatent is rendered directly from USPTO source data, no number is typed in by an editor. This page draws directly on USPTO source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of May 2026.